A focus on the development of a novel strategy of blocking CR3 (CD11b) or CR3 (CD11b/CD18) pathways in vitro could have implications for the treatment of viral infection by manipulating antiviral-driven mechanisms. Here, CRIPTO3 is linked to viral infectious disease.